Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12920995 | 0.86 | KMT2A (0.49) | KMT2AMEN1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL12920954 | 0.81 | KMT2A (0.70) | KMT2AMEN1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL8070518 | 0.81 | KMT2A (0.44) | KMT2AMEN1ALDH1A1HTTATM | |
| SCHEMBL8069232 | 0.78 | KMT2A (0.41) | KMT2AMEN1ALDH1A1ATMGAA | |
| SCHEMBL4740056 | 0.74 | CACNA1B (0.38) | KMT2AMEN1HTT | |
| SCHEMBL12920942 | 0.73 | KMT2A (0.46) | KMT2AMEN1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL4075272 | 0.73 | CNR2 (0.43) | ALDH1A1HTT | |
| SCHEMBL5662464 | 0.73 | CNR2 (0.43) | ALDH1A1HTT | |
| SCHEMBL3923891 | 0.73 | KMT2A (0.63) | KMT2AMEN1ALDH1A1HTTATM | |
| SCHEMBL5463448 | 0.71 | KMT2A (0.44) | KMT2AMEN1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009392-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009392-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | KMT2A 3290/4885MEN1 2674/4885ALDH1A1 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.